Oryzon Genomics SA (ORY) Stock Statistics & Valuation Metrics

Oryzon Genomics SA has a market cap or net worth of €234.04M. The enterprise value is €234.01M.

Oryzon Genomics SA has 79,887,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Oryzon Genomics SA’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -2.23%.

The current PE Ratio of Oryzon Genomics SA is ―. Oryzon Genomics SA’s PEG ratio is 2.31.

In the last 12 months, Oryzon Genomics SA had revenue of 0.00 and earned -2.61M in profits. Earnings per share was -0.04.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Oryzon Genomics SA pays an annual dividend of ―, resulting in a dividend yield of ―

Oryzon Genomics SA upcoming earnings date is Jul 29, 2026, After Close (Confirmed).

Oryzon Genomics SA as a current ratio of 1.95, with Debt / Equity ratio of 6.81%

In the past 12 months, Oryzon Genomics SA has paid -2.99M in taxes.

Oryzon Genomics SA EV to EBITDA ratio is -34.19, with an EV/FCF ratio of -88.95.

Oryzon Genomics SA has €22.12M in cash and marketable securities with €7.10M in debt, giving a net cash position of €15.01M billion.

Gross margin is 94.27%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Oryzon Genomics SA is €6.48, which is 11.43% higher than the current price. The consensus rating is Moderate Buy